Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AimsAim was to assess the feasibility of serum markers to identify individuals at risk for gastro-oesophageal adenocarcinoma to reduce the number of individuals requiring invasive assessment by endoscopy.MethodsBlood samples from 56 patients with Barrett's oesophagus and 202 non-Barrett controls who previously took part in a trial assessing the accuracy of the Cytosponge for Barrett's oesophagus were assessed for serum pepsinogen (PG) 1 and 2, gastrin-17, trefoil factor 3 (TFF3) and Helicobacter pylori infection.ResultsPG1 was pathological (<50 ng/mL) in 26 patients (10.1%), none of whom had Barrett's oesophagus (p<0.001). Smoking and drinking had no influence on these results. Pathological PG1 was associated with stomach pain (p=0.029), disruption of sleep (p=0.027) and disruption of diet by symptoms (p=0.019). Serum TFF3 was not associated with any clinical parameter.ConclusionsAssessment of serum PG1 could be combined with a test for Barrett's oesophagus to identify additional patients requiring endoscopy.

Original publication

DOI

10.1136/jclinpath-2019-205700

Type

Journal article

Journal

Journal of clinical pathology

Publication Date

12/2019

Volume

72

Pages

825 - 829

Addresses

MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.

Keywords

Humans, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms, Barrett Esophagus, Pepsinogen A, Pepsinogen C, Serologic Tests, Specimen Handling, Prognosis, Risk Assessment, Risk Factors, Case-Control Studies, Feasibility Studies, Reproducibility of Results, Predictive Value of Tests, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Early Detection of Cancer, Young Adult, Biomarkers, Tumor, Trefoil Factor-3